Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase.

PURPOSE: To analyze the cases of torsade de pointes (TdP) and related symptoms reported in association with chloroquine (CQ), hydroxychloroquine (HCQ), and azithromycin (AZT) to the World Health Organization (WHO) global database of individual case safety reports (ICSRs) for drug monitoring (VigiBase) using qualitative and quantitative pharmacovigilance approaches.
METHODS: The main characteristics of the ICSRs reporting TdP with CQ, HCQ, and AZT have been summarized. Co-reported drugs with risk to cause QT prolongation have been described. Reporting odds ratios (RORs) as a measure of disproportionality for reported TdP and individual drugs have been calculated.
RESULTS: One hundred seventy ICSRs reporting TdP in association with the drugs of interest were identified (CQ: 11, HCQ: 31, CQ + HCQ: 1, HCQ + AZT: 27, AZT: 100). From these, 41 (24.3%) were received during the pandemic period (December 2019 to February 2021). The median age of the patients was 63, 53, and 63 years old for CQ, HCQ, and AZT, respectively. Reports included concomitant use of other QT-prolonging drugs (CQ 25.0%, HCQ 71.2%, AZT 64.6%). A proportion of the cases were fatal (CQ 25.0%, HCQ 8.6%, AZT 16.1%). Increased disproportionality has been found for the individual drugs and TdP: CQ (ROR: 7.41, 95% confidence interval (CI): 3.82, 12.96), HCQ (ROR: 8.49, 95% CI: 6.57, 10.98), azithromycin (ROR: 8.06, 95% CI: 6.76, 9.61). Disproportionality was also found for other related symptoms, Standardized MedDRA Query for torsade de pointes/QT prolongation (narrow): CQ (ROR: 11.95, 95% CI: 10.04-14.22); HCQ (ROR: 20.43, 95% CI: 19.13, 21.83), AZT (ROR: 7.78, 95% CI: 7.26, 8.34).
CONCLUSIONS: The prescription of CQ, HCQ, and AZT should be restricted to therapeutic indications with established positive benefit/risk profile. Doctors and patients should be aware of this potential adverse reaction especially when several risk factors are present.

Introduction

Since WHO declared international public health emergency, several drugs have been repurposed in an attempt to treat or prevent COVID-19. At the beginning of this global health threat, the Food and Drug Administration (FDA) repurposed chloroquine (CQ) and hydroxychloroquine (HCQ) for the treatment of COVID-19, revoking its emergency use authorization several months later [1]. Similarly, the randomized global platform trial for COVID-19 treatments led by the World Health Organization [2] enrolled initially patients taking these drugs, but the trial’s HCQ arm was later discontinued. Moreover, combined therapy with azithromycin is also used after one controversial trial suggested a potential benefit [3, 4]. The urge to find therapeutic solutions has prompted to heterogeneous veering decisions including conditional authorizations, emergency authorizations, or recommendation for drug utilization in compassionate use or off-label use [5].

Despite these drugs have been in the market for decades, the prospect of an increased utilization during the pandemic has prompted the interest about the safety of these medicines in a context of uncertain effectiveness [6].

CQ, HCQ, and AZT have been associated with heart rhythm disturbances including torsade de pointes (TdP), a polymorphic ventricular tachycardia often preceded by a prolonged QT interval that can led to life-threatening arrhythmia and sudden cardiac death [7]. Cardiotoxic effects associated with these drugs are considered rare to occur at therapeutic doses but several cases have been reported [8, 9].

The aim of the present study was to analyze the reported cases of TdP with chloroquine, hydroxychloroquine, and azithromycin to the World Health Organization (WHO) global database of individual case safety reports (ICSRs) using quantitative and qualitative pharmacovigilance approaches.

Methods

We searched in World Health Organization (WHO) global database of individual case safety reports (VigiBase) for ICSRs from inception on Nov. 14, 1967, and February 10, 2021. VigiBase is maintained and developed on behalf of WHO by the Uppsala Monitoring Centre (UMC), situated in Uppsala, Sweden, and includes more than 21 million ICSRs (https://www.who-umc.org/). The ICSRs were accessed using the VigiLyze tool. A de-duplicated dataset version of VigiBase was used (database version April 12, 2020).

We searched for the following preferred terms (PTs) of the Medical Dictionary for Regulatory Activities (MedDRA version 22.1; http://www.meddra.org/): “torsade de pointes”, “electrocardiogram QT-prolonged”, “ventricular tachycardia”, “Long QT syndrome” reported for chloroquine, hydroxychloroquine, and azithromycin. We also searched for ICSRs for the Standardized MedDRA Query (SMQ) for “torsade de pointes/QT-prolongation (Broad and Narrow)”. SMQs are groupings of PTs related to a defined medical condition that is investigated. The “narrow” scope yields “specificity,” while the “broad” search yields “sensitivity.” A “broad” scope includes both the “narrow” terms and the additional “broad” terms, which are often of a less-specific nature [10]. PTs included in the SMQ groups are available in table S1 (Supplementary Appendix).

The main characteristics of the ICSRs were described including reporting source, patient age, gender, drug indication, and outcome (recovery, fatal). When available, daily doses were calculated from the information on the prescribed dose and the posology indicated the ICSRs. The induction period was calculated as the time between the start of the drug treatment and clinical diagnosis of TdP in the ICSRs. Co-reported drugs with risk to cause QT prolongation and TdP according to the Arizona Center for Education & Research on Therapeutics website (https://crediblemeds.org/) were described. The drugs were classified using the AZCERT QT/TdP Risk Categories for Drugs: Known Risk of TdP (category I), Possible Risk of TdP (category II), Conditional Risk of TdP (category III), and Avoid in Congenital Long QT Syndrome (category IV).

Disproportional reporting was investigated through the calculation of the reporting odds ratio with their 95% confidence interval using Woolf’s method. Results of ROR > 1.0 indicate a higher than expected reporting rate but do not necessarily means differences on the risk probability for the adverse reaction [11, 12]. To test the consistency of the disproportionality over time, we calculated the cumulative RORs per year in the period between the years in which TdP was first reported in the database to 2020. All analyses were conducted using Stata version 14 (StataCorp LP, College Station, TX, USA).

Results

Following our search, 5691 ICSRs of TdP were found. From these, 170 ICSRs reported a drug of interest and TdP: 11 with CQ, 31 with HCQ, 1 with both HCQ and CQ, 27 with azithromycin reported in combination with CQ and HCQ, and 99 with azithromycin. Forty-one ICSRs were received during the pandemic period (December 2019 to February 2021), which represents almost one-quarter of the total ICSRs reported during the last three decades. The number of reports in 2020 (as compared with the preceded year) increased 1400% for HCQ (from 2 to 30), 375% for AZT (4 to 19), and from 0 to 3 in the case of CQ. The combination HCQ + AZT was reported only in the pandemic period but not before.

The median age of the patients was 63, 53, and 63 years old for CQ, HCQ, and AZT, respectively. Most reports of CQ and AZT involved women, 75% and 49.6%, respectively (with 13.3% of unknown gender for AZT), whereas the reporting by gender was more balanced for HCQ, 35.6% were in women and 39.0% in men, sex was not specified in 15 (25.4%). Reports of CQ originated mainly in Europe (66.7%), whereas America was the most common origin for HCQ and azithromycin reports, 76.3% and 77.7%, respectively. The most common therapeutic indications reported for CQ and HCQ were COVID-19 and autoimmune diseases; no reports suggested use in malaria. Four reports involving HCQ were overdoses. On the other hand, azithromycin was mainly use for respiratory infections but COVID-19 represented 17.3% of the cases. Main characteristics of the ICSRs are described in Table 1.

Table 1

Main characteristics of the ICSRs of TdP and CQ, HCQ, and azithromycin

Drug	Number of ICSRs; number in the pandemic period	Reporting source; region and type of reporter (n; %)	Median age (years); sex (%)	Median dose (mg/day) c	Drug indication (n; %)	Induction period, median (days)d	Recovery (n; %)	Fatal outcome (n; %)	ICSRs reporting co-prescribed QT-prolonging drugs (n; %)
Chloroquine	12a Dec 2019–Feb 2021: 4 (33.3%)	Europe (8; 66.7%), America (3; 25.0%), Asia (1; 8.3%); health professionals (9; 75.0%), unspecified reporter% (3; 25.0%)	Age 63 (37–72); 75.0% women, 25.0% men	375 (250–6250)	Rheumatoid arthritis (3; 25.0%), COVID-19 (3; 25.0), connective tissue disease (1; 8.3%), sarcoidosis (1; 8.3%), photo dermatosis (1; 8.3%), overdose (1; 8.3%); unknown (2; 16.7%)	325 (1–1461)	Recovered or recovering (7 58.3%), not recovered (1; 8.3%), unknown outcome 4 (33.3%)	1 (12.5%) a	3 (25.0%)
Hydroxychloroquine	59a, b Dec 2019–Feb 2021: 37 (62.7%)	America (45; 76.3%), Europe (12; 20.3%), Africa (1; 1.7%) Asia (1; 1.7%); health professionals (49; 83.1%), non-health professionals (4; 6.8%); unspecified reporter (6; 10.17%)	Age 53 (20–91); 35.6%, women 39.0% men 25.42 sex not specified	700 (200–60,000)	COVID-19 (30; 50.9), systemic lupus erythematosus (5; 8.5%), rheumatoid arthritis (5; 8.5%), connective tissue disease (2; 3.4%), overdose (including intentional) (3; 5.1%), connective tissue disease (2; 3.4%), unknown (14; 23.7%)	22 (1–1096)	Recovered or recovering (27; 45.8%), recovered with sequelae (2; 3.4%), not recovered (1; 1.7%), unknown outcome 29 (49.2%)	5 (8.6%) a	42 (71.2%)
Azithromycin	127b Dec 2019–Feb 2021: 28 (22.0%)	America (98; 77.2%), Europe (16; 12.6%), Asia (10; 7.9%), Africa (2; 1.6%), Oceania (1; 0.8%); health professionals (95; 74.8%), non-health professionals (7; 5.5%) unspecified reporter (25; 19.7%)	Age 63 (9–95); 49.6% women, 37.0% men, 13.4% sex not specified	500 (40–2000)	Lower respiratory tract infection (25; 19.7%), COVID-19 (22; 17.3%), upper respiratory tract infection (10; 7.9%), other infections (9; 7.1%), ill-defined disorder or unknown indication (61; 48.0%)	3.5 (0–365)	Recovered or recovering (33; 26.0%), not recovered (8; 6.3%); unknown outcome (85; 66.9%)	21 (16.1%)	82 (64.6%)

aOne ICSR included both CQ and HCQ

b27 ICSRs included both HCQ and azithromycin

cdoses were calculated from info on dose and posology available in 54 ICSRs of azithromycin, 16 ICSRs of HCQ and 10 of CQ

dinduction period was estimated from 38 ICSRs of azithromycin, 6 of CQ, and 11 of HCQ

Three (25.0%) and 42 (71.2%) ICSRs mentioned other QT-prolonging drugs in addition to CQ and HCQ respectively and 82 (64.6%) ICSRs in addition to azithromycin. From these, the median number of co-prescribed QT-prolonging drugs was 1 drug (1–3) for CQ and HCQ and 1 drug (1–5) for azithromycin. At least one AZCERT category I drug was co-reported in 63 (49.6%) reports with azithromycin, 36 (61.0%) reports with HCQ, and in 3 reports with CQ (25.00%). From the total five and sixty-four QT-prolonging drugs that were co-reported with CQ and HCQ, respectively, AZT (42.2%) followed by amiodarone (6.3%) and propofol (6.3%) was the most co-prescribed with HCQ. From the 129 co-reported QT-prolonging drugs with azithromycin, HCQ (17.8%), amiodarone (7.0%), furosemide (7.00%), and salbutamol (5.4%) were the most frequent drugs (Table S2, Supplementary Appendix.)

A very consistent disproportionality was found for the individual drugs and TdP: CQ (ROR: 7.41, 95% CI: 3.82–12.96), HCQ (ROR: 8.49, 95% CI: 6.57–10.98), AZT (ROR: 8.06, 95% CI: 6.76–9.61). Moreover, disproportionality was also found for all related symptoms: Electrocardiogram QT prolonged (PT), long QT syndrome (PT), ventricular tachycardia (PT), and SMQ torsade de pointes/QT prolongation (narrow) (Table 2). Cumulative RORs since the first TdP reported in VigiBase in 1991 show that azithromycin disproportionality has been statistically significant during all the study period, whereas CQ and HCQ reached the threshold of disproportionality in 2011. The cumulative analysis shows that in 2020 there was an increase in the magnitude of the disproportionality for the three drugs and especially for HCQ (Fig. 1).

Table 2

Reporting odds ratio (ROR) values for individual drugs and TdP and related symptoms

	Cases/non cases		ROR (95% CI)
	Exposed	Non-exposed
Chloroquine
Torsade de pointes	12/6918	5679/24,253,501	7.41 (3.82–12.96)
Electrocardiogram QT prolonged	111/6819	22,216/24,236,964	17.41 (14.43–21.01)
Long QT syndrome	2/6928	952/24,258,228	7.36 (1.84–29.46)
Ventricular tachycardia	10/6920	13,481/24,245,699	2.60 (1.40–4.83)
SMQ torsade de pointes/QT prolongation (broad)	220/6710	356,207/23,902,973	2.20 (1.92–2.52)
SMQ torsade de pointes/QT prolongation (narrow)	130/6800	38,752/24,220,428	11.95 (10.04–14.22)
Hydroxychloroquine
Torsade de pointes	59/29,891	5632/24,230,528	8.49 (6.57–10.98)
Electrocardiogram QT prolonged	803/29,147	21,524/24,214,636	30.99 (28.99–33.29)
Long QT syndrome	47/29,903	907/24,235,253	42.00 (31.32–56.32)
Ventricular tachycardia	77/29,873	13,414/24,222,746	4.65 (3.27–5.82)
SMQ torsade de pointes/QT prolongation (broad)	1175/28,775	355,252/23,880,908	2.74 (2.59–2.91)
SMQ torsade de pointes/QT prolongation (narrow)	930/29,020	37,952/24,198,208	20.43 (19.13–21.83)
Azithromycin
Torsade de pointes	127/68,496	5564/24,191,923	8.06 (6.76–9.61)
Electrocardiogram QT prolonged	613/68,010	21,714/24,175,773	10.04(9.26–10.88)
Long QT syndrome	47/68,576	907/24,196,580	18.28 (13.64–24.52)
Ventricular tachycardia	131/68,492	13,360/24,184,127	3.46 (2.91–4.11)
SMQ torsade de pointes/QT prolongation (broad)	1452/67,171	354,975/23,842,512	1.45 (1.38–1.53)
SMQ torsade de pointes/QT prolongation (narrow)	831/67,792	38,051/24,159,436	7.78 (7.26–8.34)

SMQ Standardized MedDRA Query

Fig. 1

Cumulative Reporting Odds Ratio (ROR) values for individual dugs and TdP per year (Fig. 1a CQ; Fig. 1b HCQ; Fig. 1c Azithromycin)

Discussion

Increased disproportionality—a subtype of drug pharmacovigilance signal—was found for the three drugs and TdP and also for “electrocardiogram QT prolonged (PT)” which often precedes the TdP. The electrophysiological mechanism for drug-induced TdP is usually explained by the potential of these drugs to block the potassium channels and inhibit the delayed rectifier potassium current (IKr) leading to early after depolarization and resulting in QT interval prolongation [13]. Drug-induced QT/QTc interval prolongation is not specific but a sensitive surrogate indicator for drug-induced TdP risk and despite its limited specificity, it is considered the best marker available for TdP [8, 14]. The threshold of disproportionality was reached using the “narrow SMQ” approach for torsade de pointes/QT prolongation but only a marginal disproportionality was found when the “broad SMQ” was used. The use of broad SMQ describes conditions other than QT prolongation and TdP and can result in a decreased specificity and a weaker (diluted) signal [10, 15]. Disproportionality was observed for TdP and azithromycin in a previous study performed in the US FDA AERS database [16]. Several individually reported cases of TdP included in this study have been described in detail elsewhere [17-35].

In our study, most cases reporting TdP were in females and co-prescribing with drugs that can prolong the QT was common. Consistently, the effects of drugs in the QT interval have been described to be greater in women [36] and have been considered a risk factor for HCQ-induced TdP [37, 38]. Moreover, concomitant medication known to prolong the QT may have a synergistic effect in QT prolongation risk. However, co-administration of drugs categorized as “Known Risk of TdP” by the AZCERT (category I) can play a major role in arrhythmia risks beyond the absolute number of co-prescribed drugs [39]. In our study, almost one-third of the reports of HCQ and azithromycin, and a quarter of the reports of CQ have at least one co-reported drug of category I. Congenital hereditary long QT syndrome is another important risk factor that was identified in one report with CQ. Moreover, inherited arrhythmia syndromes occur in younger patients (children or adolescents) [40]. Four reports with azithromycin were in younger than 18 years old.

HCQ and CQ are 4‐amino‐quinolines antimalarial drugs structurally related to quinidine, an anti-arrhythmic drug with known QT-prolonging effects and that has been also associated with QT-related malignant arrhythmias [40]. Hydroxychloroquine sulfate is the hydroxylated analog of chloroquine [41]. After World War II, these drugs were repurposed as antirheumatic drugs [42]. Drug repositioning (also known as drug repurposing or drug reprofiling) is a process of developing new indications for existing drugs [43]. Despite CQ being the most widely used antimalarial drug in history [9], in our study, reports of TdP and HCQ or CQ mostly originated in Europe and North America for the treatment of autoimmune diseases and for the treatment of COVID-19 from 2020 onwards. Several reasons could be hypothesized to explain the absence of reports for the treatment (or prophylaxis) of malaria. First, the patients treated for malaria are probably younger, healthier, and treated with shorter treatment regimens than the chronic rheumatic patients in which the longer treatments and the autoimmune disease itself are risk factors [37, 44]. Second, the malaria-endemic areas are located in countries in which the pharmacovigilance systems are less mature; thus, the ability to detect and report rare events can be also limited [45]. Third, despite the wide use of these drugs in malaria, very few studies have evaluated its potential arrhythmogenic cardiotoxicity. A systematic review found only 1076 participants from 17 studies of chloroquine that underwent ECG investigation making unable pooled estimates of QT interval changes in malaria [46]. The narrow therapeutic range of chloroquine led WHO to recommend that its parenteral use should be discontinued in 1984 [9]. CQ and HCQ are extremely toxic in overdose. Several chloroquine-related deaths have been recently reported in Africa and Arizona [6]. In 2018, the American Association of Poison Control Centers registered three fatal cases associated with HCQ [47]. In our study, four reports were overdoses in the context of suicide attempt. Three patients took 800 mg, 4 g, and 60 g of HCQ respectively and recovered after intralipid emulsion therapy [17, 21, 28]. A fourth report was a fatal case after an intentional overdose combining 6.2 g of CQ and 6 g of HCQ.

Azithromycin is a semi-synthetic macrolide antibiotic approved in the early 1990s widely used in monotherapy to treat respiratory tract infections, Chlamydia trachomatis infections, and/or male non-gonococcal urethritis [8]. Azithromycin is one of the most consumed antibiotics in the world [48-52] and has also the highest absolute number of reported cases of TdP (and fatal cases) of the three studied drugs. After a cohort study was published in 2012 [53], the FDA released a warning in 2013 regarding the risk of potentially fatal heart rhythms associated with azithromycin [54]. Despite the potential notoriety bias that might have affected the disproportionality, in our study, the cumulative reporting analyses show that disproportionality was already statistically significant 18 years before the FDA safety announcement. Azithromycin-induced QT prolongation has been shown to start within hours to days of initiating therapy [55]. In our study, the median induction period for TdP with azithromycin was 3.5 days, shorter than in the reports of CQ or HCQ. Nevertheless, results should be interpreted with caution since one third of the ICSRs did not mention the induction period. Subsequent observational studies have reported conflicting findings [55, 56]. The absolute risk seems to be small in general population, but it may be increased in subpopulations with risk factors and comorbidity.

The FDA provided initially an emergency use authorization in COVID-19 for HCQ and CQ. The authorization was revoked months later based on FDA’s continued review which concluded that these drugs were unlikely to be effective [2]. Moreover, the latest results from randomized clinical trials had not found any efficacy for these drugs in the treatment of COVID-19 [57-59].

Consistently with the wide use of these drugs, we observed an important increase in the absolute number of reports of CQ, HCQ, and AZT reported from 2020 onwards, which represented almost one-quarter of the total ICSRs reported in the last three decades. TdP was also disproportionately reported higher than expected than other adverse reactions. Despite the revocation of emergency use authorization, seven reports with HCQ and one with chloroquine that originated in the USA were reported in 2021, suggesting that these drugs perhaps are still utilized off-label. It is important to note that safety issues can occur after a drug is repositioned especially when the drug became extensively used and the less known (or less frequent) adverse reactions emerge [60]. Not surprisingly, a small trial (N = 35) analyzing the effects of the combined therapy with high doses of chloroquine plus ceftriaxone and azithromycin in COVID-19 was prematurely stopped for safety reasons. Seven (25%) patients receiving 1200 mg daily of CQ presented QTc prolongation and two (7%) had ventricular tachycardia before death [61].

Limitations

Our study also has several limitations. Causal associations cannot (and should not) be made using data from spontaneous reports [50]. Reports of TdP lack full details on the diagnosis (i.e., ECG intervals). Data on known risk factors such as congenital QT syndrome can be lacking from the reports. Moreover, the preferred term “torsade de pointes” although very specific can present some degree of misclassification. Therefore, we have included in the analysis SMQs and related symptoms such as ventricular tachycardia and long QT syndrome and found consistent disproportionality. The possibility of duplicate reporting cannot be excluded. Notwithstanding, a de-duplicated dataset version of VigiBase was used. In addition, the TdP reports were manually reviewed for duplicates. Lastly, spontaneous reporting databases can be useful to identify rare adverse reactions. Pharmacovigilance databases share inherent limitations that have been described elsewhere [62].

In conclusion, the retrospective analysis of a large global pharmacovigilance database has allowed us to find disproportionality at individual drug level which otherwise would have been difficult to address using smaller national databases [63]. The prescription of CQ, HCQ, and AZT should be restricted to therapeutic indications with established positive benefit/risk profile. Doctors and patients should be aware of the potential cardiotoxic effect of these drugs [64]. Therefore, the shared decision for prescribing should balance the benefit against the potential risk of arrhythmia especially when several risk factors are present.

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 72 KB)